HOME >> BIOLOGY >> NEWS
Timing is everything for optimum combined cancer therapy

r a short time, makes the existing tumor vasculature more like that of normal tissues, thereby facilitating oxygen delivery to the tumor and enhancing the effects of radiation treatment.

"The time course of this vascular normalization should be taken into account when radiation and antiangiogenic therapy are combined," suggests Dr. Jain. He further speculates that, "If the time course of vascular changes induced by VEGF blockade is taken into account, one might achieve a survival advantage greater than the five months seen in the recent landmark clinical trial of combination therapy."


'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2879
Cell Press
20-Dec-2004


Page: 1 2

Related biology news :

1. Timing is everything
2. Timing of food consumption activates genes in specific brain area, researchers find
3. Timing is everything: First step in protein building revealed
4. Timing scavenging to prevent age-related blindness
5. Sugar and spice and everything nice: Health differences in newborn girls and boys
6. Good connections are everything
7. Illinois research zeroing in on optimum soil nitrogen rates
8. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
9. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids
10. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
11. Study provides first-ever look at combined causes of North Atlantic and Arctic Ocean freshening

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology ... VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to severe ...
(Date:8/21/2020)... LEXINGTON, Mass. (PRWEB) , ... August 18, 2020 ... ... novel approaches to cell therapy, today announced that the U.S. Food and Drug ... evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, ... have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access ... J&J have annual Research and Development spending in excess of US $10 billion. ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, ... its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at ... requiring fast track capacity to provide patients with urgently needed vaccines and other ...
(Date:7/31/2020)... MIAMI (PRWEB) , ... July 29, 2020 , ... ... nearly 200 of the top radiation centers in 16 countries, has reached its ... years, SDX® is now in routine use at top universities including University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... aid in the early detection and prevention of high-burden diseases, and Centric Consulting, ... hospitals and healthcare organizations to utilize existing data in order to identify and ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
Breaking Biology Technology:
Cached News: